Munis Mercedes A, Chen Qiaoling, Hill T Matthew, Zhuo Min, Schachter Asher D, Bhandari Simran K, Hever Aviv, Harrison Teresa N, Fernandes Ancilla W, Sim John J
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey.
Clin J Am Soc Nephrol. 2024 Dec 12;20(2):229-38. doi: 10.2215/CJN.0000000590.
Primary FSGS is a rare immune mediated glomerulopathy that accounted for 16.6% for all FSGS reported biopsies among a diverse patient population. From 2010 to 2021, the standardized incidence of primary FSGS was estimated at 1.7 cases per 100,000 patient-years. The highest incidence of primary FSGS was observed among Black (3.2) and Asian (2.7 cases per 100,000 patient-years) people.
Focal segmental glomerulosclerosis (FSGS) refers to a pattern of glomerular injury but also includes primary FSGS which is considered as an immune-mediated glomerulopathy. We sought to determine the incidence of primary FSGS and proportion of patients with FSGS who have primary FSGS among a large diverse patient population in the United States.
A cross-sectional study (2010–2021) was performed within an integrated health system in patients (age 18 or older) with biopsy-proven FSGS. Among biopsies with FSGS as the first diagnosis on pathology report, chart reviews were performed to determine primary FSGS, defined as podocyte foot process effacement ≥80% on electron microscopy. The proportion of patients with primary FSGS and annual incidence rate (IR) (per 100,000 patient-years) were calculated. Standardized IR were determined by age, sex, and race and ethnicity based on US population structure of the 5-year (2018–2022) American Community Survey estimates.
We identified 3838 patients with FSGS reported on biopsy. Among 1502 with FSGS as the principal diagnosis, 637 met criteria for primary FSGS (mean [SD] age 55.5 years [17.9], 56.5% male, 35.6% Hispanic, 28.7% White, 17.9% Asian/Pacific Islander, and 16.0% Black). The mean standardized IR (confidence interval) of primary FSGS was 1.7 (0.9 to 2.5) per 100,000 patient-years during the study period. The standardized annual IR ranged from 1.3 to 2.4 per 100,000 patient-years. IR (per 100,000 patient-years) were highest among Black (3.2), Asian (2.7), and Pacific Islander (2.8) patients.
Primary FSGS accounted for 16.6% of biopsy-proven FSGS. Primary FSGS is a likely a rare disease with incidence highest among Black, Asian, and Pacific Islander people. More precise identification of primary FSGS may facilitate work to improve understanding of this glomerulopathy and improve kidney outcomes.
原发性局灶节段性肾小球硬化症(FSGS)是一种罕见的免疫介导性肾小球病,在不同患者群体中,其在所有经活检确诊的FSGS病例中占16.6%。2010年至2021年期间,原发性FSGS的标准化发病率估计为每10万患者年1.7例。原发性FSGS发病率最高的是黑人(每10万患者年3.2例)和亚洲人(每10万患者年2.7例)。
局灶节段性肾小球硬化症(FSGS)指的是一种肾小球损伤模式,但也包括被视为免疫介导性肾小球病的原发性FSGS。我们试图确定美国大量不同患者群体中原发性FSGS的发病率以及患有原发性FSGS的FSGS患者比例。
在一个综合医疗系统内对年龄18岁及以上经活检证实为FSGS的患者进行了一项横断面研究(2010 - 2021年)。在病理报告中将FSGS作为首要诊断的活检病例中,进行病历审查以确定原发性FSGS,其被定义为电子显微镜下足细胞足突消失≥80%。计算原发性FSGS患者的比例和年发病率(每10万患者年)。根据2018 - 2022年美国社区调查估计的美国人口结构,按年龄、性别、种族和族裔确定标准化发病率。
我们确定了3838例经活检报告患有FSGS的患者。在以FSGS作为主要诊断的1502例患者中,637例符合原发性FSGS的标准(平均[标准差]年龄55.5岁[17.9],56.5%为男性,35.6%为西班牙裔,28.7%为白人,17.9%为亚洲/太平洋岛民,16.0%为黑人)。在研究期间,原发性FSGS的平均标准化发病率(置信区间)为每10万患者年1.7(0.9至2.5)例。标准化年发病率范围为每10万患者年1.3至2.4例。发病率(每10万患者年)在黑人(3.2)、亚洲人(2.7)和太平洋岛民(2.8)患者中最高。
原发性FSGS占经活检证实的FSGS的16.6%。原发性FSGS可能是一种罕见疾病,在黑人、亚洲人和太平洋岛民中发病率最高。更精确地识别原发性FSGS可能有助于增进对这种肾小球病的了解并改善肾脏疾病的治疗效果。